Serum Vascular Endothelial Growth Factor-D Levels in Patients With Lymphangioleiomyomatosis Reflect Lymphatic Involvement

被引:99
|
作者
Glasgow, Connie G.
Avila, Nilo A. [3 ]
Lin, Jing-Ping [2 ]
Stylianou, Mario P. [2 ]
Moss, Joel [1 ]
机构
[1] NHLBI, Translat Med Branch, NIH, Div Prevent & Populat Sci, Bethesda, MD 20892 USA
[2] NHLBI, Off Biostat Res, Div Prevent & Populat Sci, Bethesda, MD 20892 USA
[3] NIH, Warren G Magnuson Clin Ctr, Dept Diagnost Radiol, Bethesda, MD 20892 USA
关键词
adenopathy; angiomyolipoma; cystic lung disease; lymphangioleiomyoma; lymphatics; tuberous sclerosis complex; vascular endothelial growth factor-D; TUBEROUS SCLEROSIS COMPLEX; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; TSC2; WOMEN; LAM; LYMPHANGIOMYOMATOSIS; LYMPHANGIOGENESIS; TRANSPLANTATION; MUTATIONS; MECHANISM;
D O I
10.1378/chest.08-1160
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder affecting primarily women of child-bearing age, and characterized by cystic lung destruction, tumors of the kidney (angiomyolipomas [AMLs% and involvement of the axial lymphatics (lymphangioleiomyomas). Patients with LAM experience loss of pulmonary function attributed to the proliferation of abnormal-appearing smooth muscle-like cells (LAM cells). it is possible to group the LAM population by the presence or absence of extrapulmonary involvement (eg, AMLs, lymphangioleiomyomas, chylous effusions). Serum vascular endothelial growth factor (VEGF)-D, a lymphangiogenic factor, is higher in LAM patients than in healthy volunteers and has been proposed as a tool in the differential diagnosis of cystic lung disease. We assessed serum VEGF-D concentrations in relationship to clinical phenotype in LAM patients. Methods: Serum VEGF-D levels were quantified by enzyme immunosorbent assay for 111 patients with LAM and 40 healthy volunteers. VEGF-D levels in patients with pulmonary LAM, with or without extrapulmonary manifestations, were compared to those of healthy volunteers. Results: Serum VEGF-D levels were greater in patients with LAM compared to those of healthy volunteers (p < 0.001). However, when patient samples were grouped based on the extent of lymphatic extrapulmonary involvement (eg, lytnpbaingioleiomyomas and adenopathy), the statistical difference was maintained only for patients with LAM with lymphatic involvement (p < 0.001), not for those patients whose disease was restricted to the lung. Serum VEGF-D levels are a good biomarker for lymphatic involvement (area under the curve [AUC], 0.845; p < 0.0001), and a fair predictor for LAM disease (AUC, 0.7.51; p < 0.0001). Serum levels correlated to CT scan grade (p = 0.033). Conclusions: Serum VEGF-D concentration is a measure of lymphatic involvement in patients with LAM. (CHEST 2009; 135.1293-1300)
引用
收藏
页码:1293 / 1300
页数:8
相关论文
共 50 条
  • [31] Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis
    Gagné, D
    Pagé, M
    Robitaille, G
    Hugo, P
    Gosselin, D
    HUMAN REPRODUCTION, 2003, 18 (08) : 1674 - 1680
  • [32] Serum Levels of Vascular Endothelial Growth Factor in Gastric Cancer Patients
    Eroglu, Aydan
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (02) : 222 - 222
  • [33] Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells
    Akahane, M
    Akahane, T
    Matheny, SL
    Shah, A
    Okajima, E
    Thorgeirsson, UP
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (04) : 841 - 849
  • [34] Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma
    Yokoyama, Y
    Charnock-Jones, DS
    Licence, D
    Yanaihara, A
    Hastings, JM
    Holland, CM
    Emoto, M
    Umemoto, M
    Sakamoto, T
    Sato, S
    Mizunuma, H
    Smith, SK
    BRITISH JOURNAL OF CANCER, 2003, 88 (02) : 237 - 244
  • [35] Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma
    Y Yokoyama
    D S Charnock-Jones
    D Licence
    A Yanaihara
    J M Hastings
    C M Holland
    M Emoto
    M Umemoto
    T Sakamoto
    S Sato
    H Mizunuma
    S K Smith
    British Journal of Cancer, 2003, 88 : 237 - 244
  • [36] Vascular endothelial growth factor-D plasma levels in fluid overload and cardiac function evaluation of elderly patients with cardiovascular disease
    Li, Jun
    Li, Xiao-Lin
    Liu, Fa-Hu
    Yu, Ya-Fen
    Du, Yuan
    MEDICINE, 2023, 102 (46) : E36062
  • [37] Vascular endothelial growth factor-D plasma levels and VEGFD genetic variants are independently associated with outcomes in patients with cardiovascular disease
    Davidsson, Pia
    Eketjall, Susanna
    Eriksson, Niclas
    Walentinsson, Anna
    Becker, Richard C.
    Cavallin, Anders
    Bogstedt, Anna
    Collen, Anna
    Held, Claes
    James, Stefan
    Siegbahn, Agneta
    Stewart, Ralph
    Storey, Robert S.
    White, Harvey
    Wallentin, Lars
    CARDIOVASCULAR RESEARCH, 2023, 119 (07) : 1596 - 1605
  • [38] Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance
    Achen, Marc G.
    Stacker, Steven A.
    GROWTH FACTORS, 2012, 30 (05) : 283 - 296
  • [39] Increased Expression of Vascular Endothelial Growth Factor-D Following Brain Injury
    Nag, Sukriti
    Manias, Janet
    Eubanks, James H.
    Stewart, Duncan J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)
  • [40] Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sezary syndrome
    Sakamoto, Minami
    Miyagaki, Tomomitsu
    Kamijo, Hiroaki
    Oka, Tomonori
    Takahashi, Naomi
    Suga, Hiraku
    Yoshizaki, Ayumi
    Asano, Yoshihide
    Sugaya, Makoto
    Sato, Shinichi
    JOURNAL OF DERMATOLOGY, 2018, 45 (01): : 95 - 99